Table 1.
Positive hits and their kinase targets
| Hits | SELLECK compound | Main targets |
|---|---|---|
| F13 | PF-00562271 | PTK254 |
| H17 | PF-03814735 | AURKA, AURKB, FLT3, NTRK1, PTK255 |
| K17 | BI2536 | PLK1, PI3K56 |
| B19 | Crenolanib (CP-868596) | PDGFRα, PDGFRβ,57FLT3 (www.selleckchem.com) |
| F19 | Fedratinib (TG101348, SAR302503) | JAK258 |
| J19 | GSK1070916 | AURKB, AURKC59 |
| N9 | Fostamatinib (R788) | SYK60 |
Columns from the left report: the identification number (ID) of the compounds based on their position within the 384-well plate, the name of the compounds, and their main kinase targets. Compounds shown to specifically increase adeno-associated virus (AAV) transduction are F13, H17, and K17. Targets that are inhibited by more than one compound are highlighted in bold.